Gå frakoblet med Player FM -appen!
Newer NNRTI Agents in Clinical Practice
Manage episode 371092380 series 2065653
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?
Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
211 episoder
Manage episode 371092380 series 2065653
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?
Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
211 episoder
Alle episoder
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.